Androgens and Acne: Perspectives on Clascoterone, the First Topical Androgen Receptor Antagonist
April 2021
in “
Expert opinion on pharmacotherapy
”
New to Clascoterone? There is a guide in the encyclopedia. Read the guide → 
Studysummary This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In a review of clascoterone, the first FDA-approved topical androgen receptor antagonist for acne treatment, it was found to be effective and safe in a Phase III clinical trial with 1,440 participants. The trial showed significant reductions in both non-inflammatory and inflammatory acne lesions at week 12, with 18.4% and 20.3% of patients achieving treatment success, compared to 9.0% and 6.5% with a placebo. Clascoterone works by binding to androgen receptors in sebaceous glands and hair follicles, reducing sebum production and acne without systemic effects. Only 13 mild treatment emergent adverse events were reported, and no systemic anti-androgen exposure was observed. While the study was limited by small subgroup sample sizes and did not consider the impact of other acne therapies, clascoterone is considered a promising new treatment for acne and is also being investigated for androgenetic alopecia.
